(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -12.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Nektar Therapeutics's revenue in 2024 is $90,122,000.On average, 5 Wall Street analysts forecast NKTR's revenue for 2024 to be $13,245,454,847, with the lowest NKTR revenue forecast at $4,076,315,537, and the highest NKTR revenue forecast at $17,015,863,101. On average, 5 Wall Street analysts forecast NKTR's revenue for 2025 to be $12,051,204,565, with the lowest NKTR revenue forecast at $4,204,848,009, and the highest NKTR revenue forecast at $17,015,863,101.
In 2026, NKTR is forecast to generate $11,140,460,193 in revenue, with the lowest revenue forecast at $4,333,380,481 and the highest revenue forecast at $17,941,296,899.